Elanco vs Organon
Organon reported revenue of $6.2 billion in fiscal 2025, 1.3 times Elanco's $4.7 billion in fiscal 2025. Elanco's revenue grew 6.2% in its latest year, and Organon's fell 2.9%. Free cash flow was $284 million at Elanco and $538 million at Organon.
Side by side
| Elanco | Organon | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $4.7B | $6.2B |
| Revenue growth | 6.2% | −2.9% |
| Revenue growth a year, last 5 years | 7.6% | −1.0% |
| Gross margin | 55.0% | 53.3% |
| Operating margin | — | — |
| Net margin | −4.9% | 3.0% |
| Free cash flow | $284M | $538M |
| Free cash flow margin | 6.0% | 8.7% |
| Return on capital | −0.1% | 5.3% |
| Net debt to EBITDA | 5.2x | 6.3x |
| Dividends and buybacks | $0M | $88M |
| Change in diluted share count | −0.2% | 0.6% |
| Last close | $22.96 | $13.74 |
| P/E at the last close | — | 17.6× |
| Insider trades, last 12 months | bought $2.6 million, sold $100,050 | bought $854,704, sold $200,307 |
| Piotroski F-score | 6 of 9 | 5 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
ElancoOrganon
Operating margin
Percent of revenue
ElancoOrganon
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ElancoOrganon